Tag: Bharat Biotech
Bharat Biotech begins clinical trials of Spanish TB vaccine, MTBVAC in...
MTBVAC is being developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG for newborns, and for the prevention of TB disease in adults
India’s Evergreen Vaccine Story
India's biotechnology industry is positioned to become a significant engine of the Indian economy, writes Suchitra Ella, Managing Director, Bharat Biotech International Limited
BioVoice eMagazine February 2023 Issue 2 Volume 4
Click to Read: February 2023 Edition of BioVoice eMagazine
The Cover Story in the February 2023 issue focuses on the ambitious US$ 300 billion bioeconomy...
UW-Madison Global Health Institute partners Ella Foundation to establish first-ever ‘UW-Madison...
Partnership expands the Wisconsin Idea by providing interdisciplinary collaborations with UW-Madison, the Ella Foundation, and Bharat Biotech
Bharat Biotech launches iNNCOVACC, world’s first intranasal Covid-19 vaccine
The vaccine is priced at INR 325/dose for large volume procurement by state governments and union government
BioVoice eMagazine January 2023 Issue 1 Volume 4
Click to Read: January 2023 Edition of BioVoice eMagazine
BioVoice News, India's leading B2B news media for BioTech, HealthTech and AgriTech, is celebrating its 7th anniversary...
The Rising Vaccine Superpower: India’s phenomenal rise in the new vaccine...
Garnering a massive chunk of revenue owing to Covid-19 push, India’s indigenous vaccines now proudly dominate the biopharma segment. Here we analyze the fresh impetus and the outlook
Universal COVID-19 vaccine can be game-changer for developing countries like India,...
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine
Clinical data disclosure critical for Bharat Biotech Covid-19 intranasal vaccine success:...
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, as of 22 August 2022 there are currently nine COVID-19 intranasal vaccines in Phase I and later stages of clinical development in different parts of the world
Variant-Proof SARS-CoV-2 Vaccine: a CEPI-funded ExcellGene partnership with Bharat Biotech &...
An entirely new “chimeric” spike antigen complex, different from any protein of existing SARS-CoV-2 variants, will be generated